Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study
Metrics: PDF 1175 views | HTML 1434 views | ?
Yu-Peng Wu1,*, Shao-Hao Chen1,*, Shi-Tao Wang1,*, Xiao-Dong Li1, Hai Cai1, Yun-Zhi Lin1, Xue-Yi Xue1, Yong Wei1, Qing-Shui Zheng1, Ning Xu1
1Department of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
*These authors have contributed equally to this work
Ning Xu, email: email@example.com
Keywords: infiltrating ductal carcinoma, acinar cell carcinoma, PCa, SEER
Received: December 12, 2016 Accepted: February 20, 2017 Published: March 10, 2017
Infiltrating ductal carcinoma (IDC) is a rare histologic subtype of prostate cancer. We investigated the clinicopathological features and prognosis of IDC compared with acinar cell carcinoma (ACC). We identified 3814 men diagnosed with prostate cancer between 2004 to and 2013 in the Surveillance, Epidemiology, and End Results database, including 511 IDC and 3303 ACC cases. Prostate cancer-specific survival (PCSS) was compared using univariate and multivariate Cox proportional hazards models. Generally, IDC occurred in older men (≥ 65 years old) and presented with larger sizes, and higher grades, American Joint Committee on Cancer (AJCC) stages, AJCC T stages, lymph node positive rates and metastasis rates. Men with IDC were less likely to undergo radical prostatectomy, but more likely to be treated with adjuvant radiation than men with ACC. Five-year PCSS rates were significantly worse in IDC. In the multivariate analysis, patients with ACC had a better PCSS than patients with IDC. In conclusion, IDC has unique clinicopathological characteristics and has worse prognosis than ACC. Multivariable Cox regression analysis showed that age over 85 years, higher grade and T stage, and metastasis at diagnosis were independent prognostic factors of worse survival outcomes, whereas radical prostatectomy was an independent prognostic factor of better survival outcomes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.